SCHEMBL6936901

SCHEMBL6936901

O=c1[nH]c(-c2ccc(Cl)cc2)cc(-c2ccncc2)c1-c1ccccc1

nearest known ligand 0.67

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
GCGR P47871 7/20 0.67
MAPK14 Q16539 7/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6936625 0.92 CDC7 (0.54) GCGRMAPK14
SCHEMBL6936911 0.92 CDC7 (0.54) GCGRMAPK14
SCHEMBL6936591 0.87 GCGR (0.52) GCGRMAPK14
SCHEMBL7457594 0.86 MAPK14 (0.50) GCGRMAPK14
SCHEMBL6934768 0.84 MAPK14 (0.55) GCGRMAPK14
SCHEMBL6936510 0.84 GCGR (0.55) GCGRMAPK14
SCHEMBL27505558 0.84 GCGR (0.47) GCGRMAPK14
SCHEMBL2662940 0.80 GCGR (0.97) GCGRMAPK14
SCHEMBL6932091 0.79 MAPK14 (0.56) GCGRMAPK14
SCHEMBL6935142 0.78 PIM1 (0.49) GCGRMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1328277-C Substituted pyrimidinone and pyridinone compounds and their use AMGEN INC (US) 2007-07-25 CN disclosed
US-6649604-B2 Analgesics; antidiabetic agents; antiinflamamtory agents AMGEN INC. 2003-11-18 US disclosed
US-20030073704-A1 Substituted pyridone compounds and methods of use AMGEN INC. 2003-04-17 US disclosed
US-6420385-B1 INFLAMMATORY, PAIN AND DIABETES DISEASES, AMGEN INC. 2002-07-16 US disclosed
US-6096753-A Substituted pyrimidinone and pyridone compounds and methods of use AMGEN INC. (US) 2000-08-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073704-A1 Substituted pyridone compounds and methods of use IL6, IL1B, IL1A GCGR 2219/4885MAPK14 1169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.